RxSight, Inc. Overview
Pro stress-test →RxSight is an ophthalmic medical device company specializing in Light Adjustable Intraocular Lenses (LAL) for post-cataract surgery patients. The company's proprietary RxSight system enables surgeons to customize and optimize patient vision outcomes after cataract surgery through adjustable photosensitive lenses and UV light delivery devices, addressing a significant market opportunity in the premium IOL segment.
Strategic Profile
Pro stress-test →RxSight has rapidly scaled adoption to reach 15% of North American cataract surgeons with LAL procedures capturing over 10% of the regional premium IOL market. The company's strategy focuses on clinical validation, surgeon education, device installation expansion (1,084 units installed base), and international expansion to unlock higher market penetration and drive gross margins toward 73-74%.
Competitive Landscape
Pro stress-test →RxSight operates in the premium intraocular lens (IOL) market dominated by large established medtech companies. Primary competitors include Alcon (LenSx laser-assisted cataract surgery), Bausch + Lomb, Johnson & Johnson Vision, and Carl Zeiss Meditec, all offering premium IOL alternatives. RxSight's unique value proposition is post-surgery customization rather than pre-surgery optimization, differentiating it but limiting addressable market to premium patients seeking fine-tuning.
Industry Context
RxSight, Inc. operates in Ophthalmic Medical Devices / Premium Intraocular Lenses (IOL).
Key facts
Founded: 1997 · Headquarters: Aliso Viejo, California · Revenue: $139.9M (2024) / $120-130M (2025E) · Market cap: $0.41B